Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

Background SB5 (adalimumab-bwwd) is an adalimumab biosimilar targeting tumor necrosis factor (TNF) for the treatment of chronic inflammatory diseases, including moderate-to-severe chronic plaque psoriasis.Objectives To assess the four-year persistence associated with the effectiveness and safety of...

Full description

Saved in:
Bibliographic Details
Main Authors: Giampiero Girolomoni, Steven R. Feldman, Alexander Egeberg, Luis Puig, Jinah Jung, Hojung Jung, Younju Lee
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Adalimumab
BADBIR
drug survival
psoriasis
real-world data
real-world evidence
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2434091
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items